N※N

Niraparib: How PARP Inhibition Kills Cancer Cells

  //health-fitness.news-articles.net/content/2026/ .. arib-how-parp-inhibition-kills-cancer-cells.html
  Published in Health and Fitness on Saturday, April 4th 2026 at 12:14 GMT by MedPage Today
      Locale: UNITED STATES

Understanding the Mechanism: PARP Inhibition and DNA Repair

Niraparib belongs to a class of drugs called PARP inhibitors. PARP (poly ADP-ribose polymerase) enzymes are crucial for DNA repair in all cells, but cancer cells, particularly those with defects in other DNA repair pathways (like BRCA mutations, though benefit is observed even in BRCA wild-type patients), are particularly reliant on PARP for survival. By inhibiting PARP, niraparib prevents cancer cells from repairing damaged DNA, ultimately leading to cell death. This mechanism exploits a vulnerability in cancer cells, effectively disrupting their ability to proliferate and survive.

"The brilliance of PARP inhibition isn't just about killing cancer cells directly," explains Dr. Eleanor Vance, a leading gynecologic oncologist at the University of California, San Diego. "It's about leveraging inherent weaknesses in cancer cell DNA repair mechanisms. Even in patients without BRCA mutations, the accumulation of DNA damage caused by niraparib can be significant enough to slow disease progression."

Safety Considerations and Future Directions

While niraparib offers a significant clinical benefit, it's not without side effects. Common adverse events include fatigue, nausea, diarrhea, vomiting, abdominal pain, and anemia. Importantly, the drug carries a boxed warning regarding the risk of blood clots and impaired wound healing, necessitating careful patient selection and monitoring. Physicians must weigh the potential benefits against these risks when determining appropriate treatment.

Looking ahead, research is focused on identifying biomarkers that can predict which patients are most likely to respond to niraparib, allowing for a more personalized approach to treatment. Combination therapies, exploring niraparib alongside other targeted agents or immunotherapies, are also under investigation. Furthermore, the development of next-generation PARP inhibitors with improved efficacy and reduced toxicity profiles represents an ongoing area of intense research. The initial FDA approval of niraparib has undoubtedly opened doors for further innovation in ovarian cancer treatment, offering a beacon of hope for women facing this devastating disease.